Tag: Drugs and Pharmaceuticals

C Diff Foundation Recognizes Rebiotix CEO with 2019 ‘Above and Beyond’ Award

NEW PORT RICHEY, Fla. /ScoopCloud/ — The C. Diff Foundation Board of Directors announced today that the 2019 “Above and Beyond” Award will be presented to Rebiotix CEO Lee Jones in Roseville, Minnesota. The award, given to one recipient annually, is given to a person or organization that show extraordinary dedication to C. diff patient safety, advocacy, and overall drive to improve the lives of those impacted by the infection.

Paragon BioTeck, Inc. Hosts Pearl Buck Preschool Holiday Event

PORTLAND, Ore. /ScoopCloud/ — Paragon BioTeck announces holiday event, “A Night to Remember,” scheduled Friday, Dec. 7, 2018 from 5:30 – 8 p.m. in Eugene, Ore. The event delivers a magical night of holiday sights and sounds for the families of Pearl Buck Preschool.

Leading Companies to Support C Diff Foundation 6th Annual International C.diff. Conference and Health EXPO, Nov. 8-9, Philadelphia

PHILADELPHIA, Pa. /ScoopCloud/ — The C Diff Foundation is honored to welcome leading companies to the 6th Annual International “C.diff. Awareness Conference and Health EXPO,” as they come together to make a global difference. These companies are dedicated to the prevention, diagnostics, treatments, environmental safety products and services focused on C.difficile infections and Healthcare-associated infections and whose role serves great importance in the C.diff. community.

Alejandro Arboleda Named 2018 Koch Kellan Scholar

PORTLAND, Ore. /ScoopCloud/ — Paragon BioTeck, Inc., an ophthalmic pharmaceutical and medical device company, announced today that Alejandro Arboleda has been named its 2018 Koch Kellan Scholar. Paragon Gives, a Paragon BioTeck initiative, awards the Koch Kellan Scholarship to an outstanding graduate medical student committed to elevating the standard of eye care through social responsibility and a clinical, teaching or research career in ophthalmology.

ECHO Connection – Cannabinoid-Based Education, Collaboration and Hope – Non-Profit Charitable Org Appoints New CEO Andrea Barnes

SAN DIEGO, Calif. /ScoopCloud/ — ECHO Connection, a non-profit charitable organization dedicated to educating the world, hosting collaborative platforms, and providing hope for those in need of cannabinoid-based therapies, announced today that it has appointed Andrea Barnes as its new CEO and President. Barnes will be speaking about the charity’s work in guiding families seeking the therapeutic effects of cannabinoids by connecting them with resources that can help at the 4th Annual Cannabis World Congress & Business Exposition (CWCBE) in Boston.

Paragon BioTeck Calls Emerging Leaders to Apply for 2018 Ophthalmology Scholarship

PORTLAND, Ore. /ScoopCloud/ — Paragon BioTeck, Inc., a privately-held pharmaceutical and medical device company, today announced the call for the next Koch Kellan Scholar. The annual Koch Kellan Scholarship honors one outstanding graduate medical student committed to elevating the standard of eye care through social responsibility and a clinical, teaching, or research career in ophthalmology. A Paragon Gives initiative, the scholarship reinforces the fundamental mission of Paragon BioTeck to drive innovations to address unmet and underserved medical needs.

Edmond Hooker, MD, Darrel Hicks, and Bruce Rippe Discuss Medical Mattress Contamination Issues on C.diff Spores and More, Aug. 1

TAMPA, Fla. /ScoopCloud/ — C Diff Foundation’s, “C. diff. Spores and More Global Broadcasting Network,” is honored to announce Dr. Edmond Hooker, MD – Associate Professor of Health Services Administration at Xavier University, Darrel Hicks, a well-known hospital environment specialist and educator, and Bruce Rippe, CEO of Trinity Guardion, manufacturer of the Trinity Guardion Patient Protective Barrier, as our guest speakers on August 1, 2017.

ChemDiv Selected by Arcus Biosciences as the Sole Chemistry Provider for its Discovery Screening Collection

ScoopCloud Newswire

SAN DIEGO, Calif. /ScoopCloud/ — ChemDiv Inc., a fully integrated California-based CRO, announced today that Arcus Biosciences selected ChemDiv as the sole source of molecules for Arcus’s growing HTS screening collection. This collaboration, which utilized Arcus’s medicinal chemistry knowledge and ChemDiv’s computational and synthetic chemistry expertise, has resulted in the selection of several hundred thousand structures from which Arcus expects to identify starting points for several of the discovery programs in its portfolio.

Delta Care Rx Announces Patrick White, MD, Inaugural Recipient of Delta Distinguished Scholar Award

ScoopCloud Newswire

PITTSBURGH, Pa. /ScoopCloud/ — Delta Care Rx today announced the first-ever recipient of the Delta Distinguished Scholar award. Patrick White, MD, HMDC, FACP, FAAHPM, chief medical officer of BJC Hospice, St. Louis, and assistant professor of medicine at Washington University, has received an initial $25,000 research grant, with a $500,000 lifetime potential, for study into the comparative and cost effectiveness of pharmaceuticals.

Trump’s wrong attack on Opioid Epidemic

ScoopCloud Newswire

CORTE MADERA, Calif. /ScoopCloud/ — Dr. Don Harte, chiropractic activist, says Trump’s new panel, headed by Chris Christie, to deal with the opioid epidemic, is “philosophically and scientifically dead wrong.” Dr. Harte declares, “The reason for this epidemic is clear. Orthopedists and other doctors freely prescribe Oxycontin, Fentanyl, Soma and other opioid drugs, get their patients addicted.”

Ruling Affirms Patent Claim for Paragon BioTeck’s R-Phenylephrine Hydrochloride Formulation

ScoopCloud Newswire

PORTLAND, Ore., /ScoopCloud/ — Paragon BioTeck, Inc. announces a monumental ruling handed down by the United States Patent and Trademark Office (USPTO) affirming claims made by Paragon in the patent for its R-phenylephrine hydrochloride formulation. Paragon is a privately held pharmaceutical and medical device company specializing in the development and commercialization of ophthalmic pharmaceuticals, devices and therapies.

W&L Hopes Faster FDA Publication of Potential Risk Signals for SGLT2 Inhibitors: Newest – Stroke, Thromboembolic Events, Acute Kidney Injury

NEW YORK, N.Y., April 1, 2016 (SEND2PRESS NEWSWIRE) — Weitz and Luxenberg, P.C., said today it hopes potentially fatal side effects associated with SGLT2 inhibitor drugs will be reported to consumers faster, since people taking these next-generation diabetes medications deserve to be notified of the health dangers shortly after they have been reported to the U.S. Food and Drug Administration (FDA).

Paragon BioTeck Receives EN ISO 13485:2012 Certification

PORTLAND, Ore., March 29, 2016 (SEND2PRESS NEWSWIRE) — Paragon BioTeck, Inc., a privately held pharmaceutical and medical device company, announced today that it has received EN ISO 13485:2012 certification, signifying the company’s successful implementation of an effective quality management system.

eAgile Announces the Production Launch of the eSeal RFID Solution for Sealed Caps and Closures

GRAND RAPIDS, Mich. and ZURICH, Switzerland, Jan. 26, 2016 (SEND2PRESS NEWSWIRE) — eAgile Inc., a global leader in radio frequency identification (RFID) technologies, announces the successful high-volume production launch of the eSeal heat induction solution. eSeal is the first turnkey solution engineered to integrate the benefits of RFID into the billions of caps and closures consumed by the over-the-counter pharmaceutical, nutraceutical, cosmetic and chemical manufacturers.

Weitz and Luxenberg Adds Serious Urinary Tract Infections to SGLT2 Inhibitor Injuries Probe

NEW YORK, N.Y., Dec. 7, 2015 (SEND2PRESS NEWSWIRE) — Weitz and Luxenberg, P.C., today announced that the firm has expanded the scope of its investigation into SGLT2 inhibitor drug injuries. SGLT2 inhibitor drugs include Invokana and others listed below. This move will allow the nationally known mass tort law and personal injury firm to focus on cases where people taking SGLT2 inhibitors were hospitalized after developing urosepsis (serious infection of the blood) or pyelonephritis (infection of the kidneys) from SGLT2 inhibitor-associated urinary tract infections.

Zofran Birth Defect Cases Being Accepted by Weitz and Luxenberg

NEW YORK, N.Y., April 7, 2015 (SEND2PRESS NEWSWIRE) — Weitz and Luxenberg, P.C., announced it is accepting cases of congenital heart defects and cleft facial abnormalities in children whose mothers took the prescription drug Zofran during pregnancy to relieve symptoms of morning sickness.

Weitz & Luxenberg’s Relkin Appointed to Xarelto MDL Leadership Team

NEW YORK, N.Y., Feb. 11, 2015 (SEND2PRESS NEWSWIRE) — Ellen Relkin, of counsel attorney with Weitz and Luxenberg, P.C., has been named to the plaintiffs’ steering committee created by judicial order to facilitate lawsuits against the makers of the anticoagulant drug Xarelto, the personal injury and mass tort law firm today announced.